Bai Y, et al. - Authors contemplated the expression of PD-L1, PD-1, and BRAF V600E in papillary thyroid carcinoma (PTC) with the aid of immunohistochemistry. They also inspected the clinical importance of expression status. Exclusion criteria included cases with a background of chronic lymphocytic thyroiditis (CLT). Yielded data demonstrated prominent associations between expression of BRAF V600E and that of PD-L1 and PD-1. Owing to the positive link between expression of BRAF V600E and PD-L1/PD-1, immunotherapies targeting PD-L1/PD-1 possibly proved to be effective for PTC patients with the BRAF V600E mutation, which were refractory to radioiodine therapy.